Teva's $57.5M Bargain Hunt in Biotech's Graveyard

The headline numbers: $57.5 million in upfront cash, plus assumption of certain liabilities. On top of that, Teva could pay up to $67.5 million in development milestones tied to the at-home use application, and another $20 million in commercial milestones based on future sales. If everything goes perfectly, the total reaches roughly $145 million.

For context, BioXcel's bankruptcy petition listed $100 million to $500 million in liabilities against just $10 million to $50 million in assets. The company's shares had already fallen about 89% in 2026 before the filing. This is not a company negotiating from strength.

Teva, meanwhile, is shopping from a position of comfort. The company has been building a neuroscience empire as part of its "Pivot to Growth" strategy, targeting a $5 billion innovative medicines franchise by 2030. Its CNS roster already includes AUSTEDO for movement disorders, AJOVY for migraine, and UZEDY, a fast-growing injectable for schizophrenia that recently added a bipolar indication. An olanzapine long-acting injectable is under FDA review. IGALMI slots neatly into this lineup, especially if the at-home label comes through.

Why Small Biotechs Keep Dying on the Launchpad

BioXcel's collapse isn't unique. It's becoming a pattern, and a brutal one.

Public life sciences companies filed 28 bankruptcies in 2024, followed by 18 in 2025. The numbers dipped slightly, but analysts at PwC say Chapter 11 filings across industries hit a 10-year high in 2025 and expect elevated restructuring activity to continue through 2026. The targets aren't just pre-revenue startups burning through venture cash. Of the 46 life sciences bankruptcies tracked in 2024 and 2025, 19 companies had meaningful positive revenue. They were selling products. They just couldn't sell enough.

The economics are punishing. Getting a drug approved is brutally expensive. Commercializing it, building a sales team, navigating hospital formularies, and educating doctors costs even more. For a small biotech with one product, there's almost no margin for error. If the launch stumbles (and most do), the cash runway evaporates fast. BioXcel burned through its reserves in textbook fashion: approximately $65.2 million in cash at the start of 2024, down to $30 million by year-end, then just $17.2 million by March 2026.

By May 2026, BioXcel publicly announced it was exploring strategic alternatives. Three months later, it was in bankruptcy court.

The Vultures Are Circling (and That's Not Necessarily Bad)

What happens to BioXcel's assets is, in many ways, the system working as intended. Bankruptcy doesn't mean IGALMI disappears; it means the drug finds an owner with deeper pockets and better distribution. Teva has the hospital relationships, the sales infrastructure, and the CNS expertise to give IGALMI a real shot.

The broader trend is worth watching. Distressed biotech acquisitions increasingly feature stalking horse bids, credit bids from lenders, and quick asset sales rather than drawn-out restructurings. Companies like Omega Therapeutics, Molecular Templates, and Synthego all went through similar processes in 2025. The buyers are typically secured lenders, strategic acquirers, or sponsors who know the space well.

For Teva, this is a calculated bet. The upfront price of $57.5 million is modest by pharma standards. If the at-home expansion wins FDA approval and Teva's commercial machine can do what BioXcel's couldn't, IGALMI could become a meaningful contributor to the neuroscience portfolio. If the expansion stalls, Teva is out a manageable sum and still owns a niche hospital product.

The Bottom Line

BioXcel's story is a cautionary tale about the gap between FDA approval and commercial success. Getting a drug across the regulatory finish line is only half the race; selling it is the other half, and it's the half that kills small companies.

Teva saw a good drug trapped inside a bad balance sheet and pounced. The bankruptcy court will decide whether anyone wants to bid higher. But regardless of who ends up owning IGALMI, the lesson is clear: in biotech, approval is not a business model. Distribution is.

One Shot to Rewrite Your Cholesterol Forever

CRISPR Therapeutics just showed that a single IV infusion can slash cholesterol and triglycerides for at least a year by permanently editing a gene in liver cells. The one-year Phase 1a data for CTX310 are stunning, but the jump from 15 patients to the real world is where things get interesting.